Compare STTK & DCGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STTK | DCGO |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Managed Health Care |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.0M | 97.4M |
| IPO Year | 2020 | N/A |
| Metric | STTK | DCGO |
|---|---|---|
| Price | $3.05 | $0.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $4.00 | $3.33 |
| AVG Volume (30 Days) | 392.9K | ★ 687.1K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,000,000.00 | ★ $368,093,385.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.69 | $0.87 |
| 52 Week High | $3.38 | $5.68 |
| Indicator | STTK | DCGO |
|---|---|---|
| Relative Strength Index (RSI) | 67.21 | 36.60 |
| Support Level | $2.82 | $0.88 |
| Resistance Level | $3.30 | $0.99 |
| Average True Range (ATR) | 0.24 | 0.06 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 74.76 | 1.38 |
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company uses its care delivery platform to provide mobile health services, virtual care management, and ambulance services. It has three reporting segments: Mobile Health Services, Transportation Services, and Corporate. A majority of its revenue is generated from the Mobile Health Services segment, which includes various healthcare services performed at homes, offices, and other locations and event services such as on-site healthcare support at sporting events and concerts. Geographically, the company generates a majority of its revenue from the United States and the rest from the United Kingdom.